Tuesday, July 8, 2025
12.7 C
London
HomeFinTechNeuroScientific Biopharmaceuticals: Launches post-COVID fibrosis research program

NeuroScientific Biopharmaceuticals: Launches post-COVID fibrosis research program

Date:

Mastercard and Pay4You Unite for Enhanced Spend Management Solutions

A Game-Changing Partnership to Transform Financial Oversight for BusinessesHighlights:...

EPC Urges Directory Service Providers to Collaborate on VOP Scheme

Enhancing the Future of Payments: A Call for Collaboration...

Five More Belgian Banks Join the European Payments Initiative

Enhancing Collaboration in the Payment Landscape Across EuropeHighlights: Five...
  • NeuroScientific Biopharmaceuticals is teaming up with the Institute of Respiratory Health and the University of Western Australia to find a treatment for post-COVID fibrosis
  • Then the disease can cause lasting damage to the lungs, even in young adults, and could potentially become one of the largest future burdens on global healthcare
  • However, recent data has shown that a protein known as Metallothionein can protect the lungs from injury and fibrosis
  • This is where NSB comes in: its flagship candidate, EmtinB, designed to mimic the protein in patients
  • NSB and UWA’s will now research the protein and its viability as a post-COVID fibrosis treatment, with data set for release in the first half of 2021
  • On the market this afternoon, NSB remains steady and is trading for 34 cents per share

Related stories

spot_img

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories